A $1.9 million U.S. Department of Defense–funded Phase 2 clinical trial will test SwallowFIT, a targeted exercise program designed to retrain the brain’s ability to control the muscles involved in swallowing — a function often compromised in Parkinson’s disease — in active-duty service members, veterans, or their relatives who…
People with Parkinson’s disease have an increased abundance of the oral bacteria Streptococcus mutans — typically found in the mouth and associated with cavities in the teeth — in their gut, according to a new study involving patients and a mouse model. Once established in the gut, these bacteria…
Deep brain stimulation (DBS) can provide lasting relief from motor symptoms and help people with Parkinson’s disease function better day to day over time, while reducing the need for medication, according to a study led by University of Florida (UF) Health. The new study showed that improvements in…
ARV-102, an oral therapy Arvinas is developing for people with Parkinson’s disease, was shown to reach the brain — where it is needed — and to be safe and well tolerated over two weeks in clinical studies with healthy volunteers and patients. In the volunteers taking part in…
The oral therapy GT-02287, being developed by Gain Therapeutics for people with Parkinson’s disease with or without mutations in the GBA1 gene, was shown to ease motor symptoms and help patients maintain routine daily activities over three months while being safe and well tolerated. That’s according to interim…
Abbvie has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of tavapadon as a Parkinson’s disease treatment. Clinical data have shown that the once-daily oral small molecule appears safe, reduces motor symptoms, and prolongs periods when these symptoms are well managed. The application is…
The first patient has been dosed in exPDite-2, a registrational Phase 3 clinical trial testing the safety and efficacy of bemdaneprocel, an investigational stem cell therapy that Bluerock Therapeutics is developing for Parkinson’s disease. The trial (NCT06944522), originally scheduled to begin earlier this year, is recruiting…
Gain Therapeutics has launched a nine-month extension of its clinical trial testing GT-02287 as a Parkinson’s disease treatment. More than half of the patients who received GT-02287 for about three months as part of the Phase 1b clinical trial (NCT06732180), which is expected to be completed at…
A roundtable in the U.S. capital, hosted by the Parkinson’s Foundation, is aiming to find new ways to improve access to healthcare providers and treatment, define inroads for innovation, and align stronger policies in Parkinson’s disease care by centering patient and caregiver voices in a nationwide planning session. The…
A study showed that following the MIND diet — one that’s rich in vegetables, whole grains, legumes, nuts, and berries, and low in sugary, fried, and high-fat foods — may help maintain gut health in people with Parkinson’s disease by reducing the levels of zonulin, a protein that helps…
Get regular updates to your inbox.
